Literature DB >> 28507758

Fecal immunochemical test-based colorectal cancer screening: The gender dilemma.

Esmée J Grobbee1, Els Wieten1, Bettina E Hansen1, Esther M Stoop1, Thomas R de Wijkerslooth2, Iris Lansdorp-Vogelaar3, Patrick M Bossuyt4, Evelien Dekker2, Ernst J Kuipers1, Manon Cw Spaander1.   

Abstract

BACKGROUND: Despite differences between men and women in incidence of colorectal cancer (CRC) and its precursors, screening programs consistently use the same strategy for both genders.
OBJECTIVE: The objective of this article is to illustrate the effects of gender-tailored screening, including the effects on miss rates of advanced neoplasia (AN).
METHODS: Participants (age 50-75 years) in a colonoscopy screening program were asked to complete a fecal immunochemical test (FIT) before colonoscopy. Positivity rates, sensitivity and specificity for detection of AN at multiple cut-offs were determined. Absolute numbers of detected and missed AN per 1000 screenees were calculated.
RESULTS: In total 1,256 individuals underwent FIT and colonoscopy, 51% male (median age 61 years; IQR 56-66) and 49% female (median age 60 years; IQR 55-65). At all cut-offs men had higher positivity rates than women, ranging from 3.8% to 10.8% versus 3.2% to 4.8%. Sensitivity for AN was higher in men than women; 40%-25% and 35%-22%, respectively. More AN were found and missed in absolute numbers in men at all cut-offs.
CONCLUSION: More AN were both detected and missed in men compared to women at all cut-offs. Gender-tailored cut-offs could either level sensitivity in men and women (i.e., lower cut-off in women) or level the amount of missed lesions (i.e., lower cut-off in men).

Entities:  

Keywords:  Colorectal cancer; fecal immunochemical test; gender; miss rates; screening

Year:  2016        PMID: 28507758      PMCID: PMC5415207          DOI: 10.1177/2050640616659998

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN: 2050-6406            Impact factor:   4.623


  26 in total

1.  Interval cancers in a FOBT-based colorectal cancer population screening programme: implications for stage, gender and tumour site.

Authors:  R J C Steele; P McClements; C Watling; G Libby; D Weller; D H Brewster; R Black; F A Carey; C G Fraser
Journal:  Gut       Date:  2011-09-19       Impact factor: 23.059

2.  Burden of colonoscopy compared to non-cathartic CT-colonography in a colorectal cancer screening programme: randomised controlled trial.

Authors:  Thomas R de Wijkerslooth; Margriet C de Haan; Esther M Stoop; Patrick M Bossuyt; Maarten Thomeer; Marie-Louise Essink-Bot; Monique E van Leerdam; Paul Fockens; Ernst J Kuipers; Jaap Stoker; Evelien Dekker
Journal:  Gut       Date:  2011-12-23       Impact factor: 23.059

3.  European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition--Faecal occult blood testing.

Authors:  S P Halloran; G Launoy; M Zappa
Journal:  Endoscopy       Date:  2012-09-25       Impact factor: 10.093

Review 4.  Colorectal cancer screening: a global overview of existing programmes.

Authors:  Eline H Schreuders; Arlinda Ruco; Linda Rabeneck; Robert E Schoen; Joseph J Y Sung; Graeme P Young; Ernst J Kuipers
Journal:  Gut       Date:  2015-06-03       Impact factor: 23.059

Review 5.  Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know.

Authors:  Jill Tinmouth; Iris Lansdorp-Vogelaar; James E Allison
Journal:  Gut       Date:  2015-06-03       Impact factor: 23.059

6.  Sex is a stronger predictor of colorectal adenoma and advanced adenoma than fecal occult blood test.

Authors:  Monika Ferlitsch; Georg Heinze; Petra Salzl; Martha Britto-Arias; Elisabeth Waldmann; Karoline Reinhart; Christina Bannert; Elisabeth Fasching; Peter Knoflach; Werner Weiss; Michael Trauner; Arnulf Ferlitsch
Journal:  Med Oncol       Date:  2014-08-14       Impact factor: 3.064

Review 7.  Colorectal cancer screening and prevention in women.

Authors:  Lyssa Chacko; Carole Macaron; Carol A Burke
Journal:  Dig Dis Sci       Date:  2015-01-18       Impact factor: 3.199

Review 8.  Colorectal cancer screening--optimizing current strategies and new directions.

Authors:  Ernst J Kuipers; Thomas Rösch; Michael Bretthauer
Journal:  Nat Rev Clin Oncol       Date:  2013-02-05       Impact factor: 66.675

9.  Long-term mortality after screening for colorectal cancer.

Authors:  Aasma Shaukat; Steven J Mongin; Mindy S Geisser; Frank A Lederle; John H Bond; Jack S Mandel; Timothy R Church
Journal:  N Engl J Med       Date:  2013-09-19       Impact factor: 91.245

10.  Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy.

Authors:  Hermann Brenner; Sha Tao
Journal:  Eur J Cancer       Date:  2013-05-22       Impact factor: 9.162

View more
  12 in total

1.  Participant-Related Risk Factors for False-Positive and False-Negative Fecal Immunochemical Tests in Colorectal Cancer Screening: Systematic Review and Meta-Analysis.

Authors:  Clasine M de Klerk; Lisanne M Vendrig; Patrick M Bossuyt; Evelien Dekker
Journal:  Am J Gastroenterol       Date:  2018-08-29       Impact factor: 10.864

2.  Making FIT Count: Maximizing Appropriate Use of the Fecal Immunochemical Test for Colorectal Cancer Screening Programs.

Authors:  Vivy T Cusumano; Folasade P May
Journal:  J Gen Intern Med       Date:  2020-03-03       Impact factor: 5.128

3.  Influence of Varying Quantitative Fecal Immunochemical Test Positivity Thresholds on Colorectal Cancer Detection: A Community-Based Cohort Study.

Authors:  Kevin Selby; Christopher D Jensen; Jeffrey K Lee; Chyke A Doubeni; Joanne E Schottinger; Wei K Zhao; Jessica Chubak; Ethan Halm; Nirupa R Ghai; Richard Contreras; Celette Skinner; Aruna Kamineni; Theodore R Levin; Douglas A Corley
Journal:  Ann Intern Med       Date:  2018-09-18       Impact factor: 25.391

4.  Effect of Sex, Age, and Positivity Threshold on Fecal Immunochemical Test Accuracy: A Systematic Review and Meta-analysis.

Authors:  Kevin Selby; Emma H Levine; Cecilia Doan; Anton Gies; Hermann Brenner; Charles Quesenberry; Jeffrey K Lee; Douglas A Corley
Journal:  Gastroenterology       Date:  2019-08-22       Impact factor: 22.682

5.  Variation of diagnostic performance of fecal immunochemical testing for hemoglobin by sex and age: results from a large screening cohort.

Authors:  Hermann Brenner; Jing Qian; Simone Werner
Journal:  Clin Epidemiol       Date:  2018-04-05       Impact factor: 4.790

6.  The cumulative false-positive rate in colorectal cancer screening: a Markov analysis.

Authors:  Ulrike Haug; Veerle M H Coupé
Journal:  Eur J Gastroenterol Hepatol       Date:  2020-05       Impact factor: 2.586

7.  Rate of detection of serrated lesions at colonoscopy in an average-risk population: a meta-analysis of 129,001 individuals.

Authors:  Junjie Huang; Paul S F Chan; Tiffany W Y Pang; Peter Choi; Xiao Chen; Veeleah Lok; Zhi-Jie Zheng; Martin C S Wong
Journal:  Endosc Int Open       Date:  2021-02-19

8.  Lack of Association between Red Meat Consumption and a Positive Fecal Immunochemical Colorectal Cancer Screening Test in Khon Kaen, Thailand: a Population- Based Randomized Controlled Trial

Authors:  Putthikrai Pramual; Pongdech Sarakarn; Siriporn Kamsa-ard; Chananya Jirapornkul; Naowarat Maneenin; Prasert Thavondunstid; Prachak Juntarach; Supannee Promthet
Journal:  Asian Pac J Cancer Prev       Date:  2018-01-27

9.  Positive predictive values of fecal immunochemical tests used in the STOP CRC pragmatic trial.

Authors:  Carrie M Nielson; Amanda F Petrik; Lorie Jacob; William M Vollmer; Erin M Keast; Jennifer L Schneider; Jennifer S Rivelli; Tanya J Kapka; Richard T Meenan; Rajasekhara R Mummadi; Beverly B Green; Gloria D Coronado
Journal:  Cancer Med       Date:  2018-08-13       Impact factor: 4.452

Review 10.  Aspects of colorectal cancer screening, methods, age and gender.

Authors:  R Hultcrantz
Journal:  J Intern Med       Date:  2020-09-14       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.